Abstract | BACKGROUND: METHODS: Haploidentical family donors were selected as donor sources for a total of five patients without a suitable donor between March 2015 and March 2017. A modified transplant protocol using PTCy (50 mg/kg/day on days +3 and +4) was performed, including busulfan (16 mg/kg), fludarabine (150 mg/m2 ), and rabbit antihuman thymocyte globulin (7.5 mg/kg). RESULTS: The median time for neutrophil recovery over 1,000 × 103 /mm3 was 15 days (range, 12-18 days), and that for keeping platelets counts over 50,000/mm3 was 27.5 days (range, 20-35 days). The median follow-up was 2.1 years (range, 1.4-2.5 years). Two patients developed grade I acute graft-versus-host disease (GVHD), and one patient had limited chronic GVHD. All five patients are alive and independent of platelet infusion with 100% donor chimerism. CONCLUSION: Our pilot study suggests that HSCT with modified PTCy is a safe and effective treatment for WAS, which needs further clinical practice and research.
|
Authors | Yan Yue, Xiaodong Shi, Zeliang Song, Jiayue Qin, Junhui Li, Shunqiao Feng, Rong Liu |
Journal | Pediatric blood & cancer
(Pediatr Blood Cancer)
Vol. 65
Issue 8
Pg. e27092
(08 2018)
ISSN: 1545-5017 [Electronic] United States |
PMID | 29745014
(Publication Type: Clinical Trial, Journal Article)
|
Copyright | © 2018 Wiley Periodicals, Inc. |
Chemical References |
- Immunosuppressive Agents
- Cyclophosphamide
|
Topics |
- Child, Preschool
- Cyclophosphamide
(therapeutic use)
- Graft vs Host Disease
(prevention & control)
- Hematopoietic Stem Cell Transplantation
(methods)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Infant
- Male
- Pilot Projects
- Transplantation, Haploidentical
(methods)
- Wiskott-Aldrich Syndrome
(therapy)
|